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gene ofﬁ cial symbol gene name location Possible pathways / pathological biological processes
mendelIAn genes
SNCA Synuclein, alpha 4q21 Synaptic function; mitochondrial function; autophagy/lysosomal degradation
 PARK2 Parkin RBR E3 ubiquitin protein ligase 6q25.2-q27 Mitochondrial function/mitophagy;  ubiquitination; synaptic function
PINK1 PTEN -induced putative kinase 1 1p36 Mitochondrial function/mitophagy
PARK7/DJ-1 Parkinson protein 7 1p36.23 Infl ammation/immune system; mitochondrial function
LRRK2 Leucine-rich repeat kinase 2 12q12 Synaptic function;  infl ammation/immune system; autophagy/lysosomal degradation
 PLA2G6  Phospholipase A2, group VI 22q13.1 Mitochondrial function
 FBXO7 F-box protein 7 22q12.3 Ubiquitination; mitochondrial function/mitophagy
 VPS35 Vacuolar protein sorting 35 homolog (S. cerevisiae) 16q12 Autophagy/lysosomal degradation; endocytosis
ATP13A2 ATPase type 13A2 1p36 Mitochondrial function; autophagy/lysosomal degradation
DNAJC6 DnaJ (Hsp40) homolog, subfamily C, member 6 1p31.3 Synaptic function; endocytosis
SYNJ1 Synaptojanin 1 21q22.2 Synaptic function; endocytosis
RIsk genes
GBA Glucosidase, beta, acid 1q21 Infl ammation/ immune system; autophagy/lysosomal degradation; metabolic pathways
RIsk locI
 MAPT Microtubule-associated protein tau 17q21.1 Microtubule stabilization and axonal transport
RAB7L1 RAB7, member RAS oncogene family-like 1  1q32 Autophagy/lysosomal degradation 
 BST1 Bone marrow stromal cell antigen 1 4p15 Immune system
HLA-DRB5 Major histocompatibility complex, class II, DR beta 5 6p21.3 Infl ammation/immune system
 GAK/ Cyclin-G-associated kinase  4p16 Autophagy/lysosomal degradation; synaptic function; endocytosis
 ACMSD Aminocarboxymuconate semialdehyde decarboxylase 2q21.3 Tryptophan metabolism; metal ion binding; metabolic pathways
 STK39 Serine threonine kinase 39 2q24.3 Infl ammation/immune system; protein kinase binding; cellular stress response
 SYT11 Synaptotagmin XI 1q21.2 Synaptic function; transporter activity; metal ion binding; substrate for PARK2
 FGF20 Fibroblast growth factor 20 8p22 Growth factor activity; FGF receptor binding
 STX1B Syntaxin 1B 16p11.2 Synaptic function; SNAP receptor activity; protein domain-specifi c binding
 GPNMB Glycoprotein (transmembrane) nmb 7p15 Integrin binding; heparin binding; cancer pathways
 SIPA1L2 Signal-induced proliferation-associated 1 like 2 1q42.2 GTPase activator activity
 INPP5F Inositol polyphosphate-5-phosphatase F 10q26.11 Phosphoric ester hydrolase activity
 MIR4697HG MIR4697 host gene (non-protein coding) 11q25
 GCH1 GTP cyclohydrolase 1 14q22.1-q22.2 GTP binding; calcium ion binding; BH4 metab; metabolic pathways
 VPS13C Vacuolar protein sorting 13 homolog C (S. cerevisiae) 15q22.2 Endocytosis
 DDRGK1 DDRGK domain containing 1 20p13 Protein binding
 MCCC1 Methylcrotonoyl-CoA carboxylase 1 (alpha) 3q27 Biotin carboxylase activity; methylcrotonoyl-CoA carboxylase activity; metabolic pathways
 SCARB2 Scavenger receptor class B, member 2 4q21.1 Autophagy/lysosomal degradation; receptor activity ( lysosomal receptor for GBA targeting); 
enzyme binding
 CCDC62 Coiled-coil domain containing 62 12q24.31 Nuclear receptor coactivator; cancer pathways
 RIT2 Ras-like without CAAX 2 18q12.3 Synaptic function; calmodulin binding; GTP binding
SREBF1 Sterol regulatory element binding transcription factor 1 17p11.2 Chromatin binding; cholesterol and steroid metabolic processes
Variant frequency in the general population
Genetic landscape of Parkinson’s Disease
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Different types of genetic technologies and approaches allow for the study and identification of different types of genetic variability in a disease. Here, represented are the 
enes and genetic loci independently replicated as being associated with the development of Parkinson’s disease (PD)/parkinsonism.
Genetic analyses of familial cases (mainly genetic linkage [blue area] and, more recently, exome sequencing [green area]) have led to the identification of causative muta-
ons in 11 genes implicated in monogenic typical or atypical forms of parkinsonism. From these, eight genes have been associated with autosomal-recessive patterns 
f inheritance, either causing typical early-onset PD (PARK2, PINK1, and DJ-1/PARK7) or atypical forms of parkinsonism with juvenile onsets (ATP13A2, PLA2G6, FBXO7, 
NAJC6, and SYNJ1). Three genes have been shown to cause typical autosomal dominant PD phenotypes (SNCA, LRRK2, and VPS35) associated with early- or late-onsets 
f disease. Additionally, other genes are known to harbor mutations associated with non-PD disorders that may present with parkinsonism, for example ATXN2, ATXN3, GCH1
RN, MAPT, C9ORF72, CSF1R, TH, and SPG1. Very recently, mutations in RAB39B have been described as causing X-linked intellectual disability plus a phenotype indistin-
uishable from early-onset PD.
Other chromosomal loci (like PARK3 and PARK10, for example) have been identified by genome-wide approaches as genomic regions associated with typical PD. These 
ci may contain other, still-to-be-identified, PD genes.
Lastly, there are also some genes that have been suggested to harbor causative PD mutations, which have not been confirmed: GIGYF2, HTRA2, UCHL1, EIF4G1, and SPR.
By using genetic family studies (for LRRK2) and a candidate gene approach (for GBA), high-risk variants (with odds ratio in the range of 5–8) for the development of typical 
D have been identified in both genes (central part of the graph).
More recently, the development of whole-genome genotyping platforms (pink area of the graph) has allowed for the study of the involvement of common variants with 
w risk in the disease. This has led to the identification of 24 new genetic loci by several independent genome-wide association studies (GWAS) and meta-analyses: SNCA, 
RRK2, MAPT, RAB7L1, BST1, HLA-DRB5, GAK, ACMSD, STK39, MCCC1, SYT11, CCDC62, FGF20, STX1B, GPNMB, SIPA1L2, INPP5F, MIR4697HG, GCH1, VPS13C, SCARB2
IT2, DDRGK1, and SREBF1. Because of the way these studies are designed, they only identify genetic regions associated with disease and not specific genes or variants. Fo
is reason, if the significant single nucleotide polymorphisms (SNPs) are intergenic or the region contains more than one gene, the locus usually gets its name from the gene 
losest to the significant hit. Very few of these significant hits have a clear functional role in the disease and, because of this, follow-up work is currently underway to determin
xactly which genes and genetic variants are important for the disease and how they are exerting their effect. Recently, an unbiased screen for interactors of LRRK2 identified
e most likely candidates for two of these GWAS loci: in chromosome 1q32, the associated locus (originally named RAB7L1/NUCKS1) contained five genes, and in chromo-
ome 4p16, the associated locus (originally named GAK/TMEM175/DGKQ) contained nearly ten genes. RAB7L1 and GAK have now been identified as LRRK2 interactors and,
 this way, as the most likely hits in each region. Additionally, these proteins were shown to form a newly identified protein complex that promotes clearance of Golgi-derived 
esicles via the autophagy-lysosome system both in vitro and in vivo, clearly highlighting the role the “Autophagy/Lysosomal degradation” pathway in Parkinson’s disease.
More generally, pathway analyses of GWAS data implicated other biological processes as primary etiological events in the disease with significant overrepresentation of 
ssociation signals in pathways related to “regulation of leucocyte/lymphocyte activity,” “cytokine-mediated signaling,” “axonal guidance,” “focal adhesion,” and “calcium 
ignaling.” 
Representation of genes within each group in the graph is approximate and does not reflect differences in frequency or risk.
leomorphic Risk—Exemplified by SNCA
This panel illustrates that, at the same locus, several disease-related genetic mechanisms may co-exist, each influencing disease through different biological effects on a 
ingle gene. In this particular model, expression of a gene is positively correlated with risk shown by duplication mutations causing Parkinson’s disease. Five coding muta-
ons have been identified as the cause of disease in early-onset familial cases. Duplications and triplications of the SNCA locus have also been implicated as the cause of 
arly-onset Parkinson’s disease. Interestingly, GWAS have also identified two different association signals in this locus, representing common variability with a low effect in th
isease. Possible protective variants are also represented in the graph.
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